Funding for this research was provided by:
Health Research Council of New Zealand (14-527)
Received: 13 June 2019
Accepted: 25 September 2019
First Online: 12 November 2019
Ethics approval and consent to participate
: The New Zealand Multi-Region Ethics Committee (MEC/105/10/130) granted ethical approval for the study, and all participants gave written informed consent.
: Not applicable.
: TRM has received consulting fees or grants from Ardea Biosciences and AstraZeneca. ND has received consulting fees, speaker fees or grants from AstraZeneca/Ironwood, Kowa, Horizon, Amgen, Abbvie, Takeda, Pfizer and Janssen. The other authors declare that they have no competing interests.